# Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers

> **NCT00822185** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 32 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Healthy

## Interventions

- **DRUG:** vatreptacog alfa (activated)
- **DRUG:** vatreptacog alfa (activated)
- **DRUG:** vatreptacog alfa (activated)
- **DRUG:** vatreptacog alfa (activated)
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00822185
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2015-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00822185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00822185, "Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00822185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*